Costs & health insurance
Cost approval for cannabis: what is known about approvals
How often health insurers grant cost approval for cannabis medicines is barely published. These are the figures that exist, and what is missing.
Key points
- There is no current, public approval rate for cost approvals for cannabis medicines. evidena has no data of its own on this either.
- The most recent published figure comes from an evaluation commissioned by the FOPH: 47 per cent of applications for cannabis were approved in 2017, and 64 per cent in 2018.
- Across all medicines, the approval rate for individual-case applications was 78.2 per cent in 2019. Cannabis was therefore clearly lower.
- The rates differed widely between insurers. According to the evaluation, the data are subject to some imprecision.
- Since August 2022, the FOPH has been collecting data on prescriptions with MeCanna, but not on cost approvals.
How often a health insurer grants cost approval for cannabis medicines is barely documented publicly in Switzerland. There is no current rate for 2026. The most recent published figures come from an evaluation commissioned by the FOPH and relate to the years 2017 and 2018: at that time, 47 and 64 per cent of applications for cannabis were approved.3
These figures are eight to nine years old and date from before the 2022 change in the law. They say nothing about how your insurer decides in your individual case today. evidena has no data of its own on approvals either and therefore does not state a rate.
Cost approval for cannabis: how the insurer decides
The benefits catalogue of basic health insurance contains no cannabis medicines. According to the FOPH, the criteria of effectiveness, appropriateness and cost-effectiveness could not so far be considered met for inclusion.2
Reimbursement is therefore only possible in individual cases under Art. 71a to 71d of the Health Insurance Ordinance (KVV). The insurer only covers the costs on special approval after consulting its medical adviser. If the application is complete, it decides within two weeks. One of the requirements is that a major therapeutic benefit is expected against a disease that may be fatal or may lead to severe and chronic health impairments.1
Every approval is therefore an individual assessment. A rate only describes how many applications succeeded in a given period, not how good the chances of a particular application are.
The only published rates: the 2020 evaluation
In 2019 and 2020, the FOPH had the reimbursement of medicines in individual cases evaluated by the consultancy BSS and asim. The basis was data that the insurers supply to the FOPH. The final report is dated 24 July 2020.3
Cannabis: figures for 2017 and 2018
In a list of the ten most frequently requested medicines, cannabis ranks second. The report gives the following figures:3
| Year | new applications for cannabis | approval rate | average approved amount |
|---|---|---|---|
| 2017 | 984 | 47 % | CHF 300 |
| 2018 | 1013 | 64 % | CHF 593 |
The authors note that, by comparison, cannabis shows a low approval rate with low average approved amounts.3 Under “cannabis”, the table groups different preparations from different manufacturers.
For comparison: all medicines
Across all medicines, new applications were approved in around three quarters of cases. The rate rose from 72.6 per cent in 2017 to 78.2 per cent in 2019. In 2019, around 37,900 new applications were received.3
47 % / 64 %
How reliable these figures are
The report itself points out limitations. The insurers had different views on how to supply the data, for example whether a request for reconsideration counts as a separate application or whether a therapeutic trial counts as an approval or a rejection. The number of applications and the approval rate are therefore subject to a certain imprecision.3
Even where data were supplied comparably, there were large differences between insurers. In one group, approval rates across all medicines ranged between 46 and 74 per cent, each with more than 2,000 applications per year. The evaluation concludes that equal treatment of all insured persons cannot be assumed.3 No figures per insurer have been published for cannabis alone.
In addition, many rejections are not final. The doctors interviewed stated that they request reconsideration for around 90 per cent of rejected applications, which is approved in around half of cases. These statements come from expert interviews and apply to all medicines.3 What you can do after a rejection is described in the hub Costs and health insurance.
Older figures: exceptional authorisations and Sativex
Before August 2022, prescribing most cannabis medicines required an exceptional authorisation from the FOPH. From 2012 to 2019, the FOPH granted around 15,000 such authorisations, with the majority of applications being approved.2 These authorisations concerned access to the medicine, not cost coverage by the health insurer. They are therefore not a cost approval rate.
The Federal Council’s 2018 report gives another figure: according to the insurers, around 1,000 packs of Sativex per year were reimbursed through basic health insurance in the three preceding years. What share of this was within and what share outside the authorised indication was not known.4 No rate can be derived from this because the number of applications is missing.
What has been known since the 2022 change in the law
Since 1 August 2022, doctors have prescribed cannabis medicines without FOPH authorisation and report the treatment in the MeCanna system. The first report on this appeared in February 2025 and covers the period up to 31 July 2023. In that year, 724 reports were received from 384 doctors. The FOPH assumes that the reporting obligation is not being fully complied with.5 The report contains no information on cost coverage.5
The change in the law did not address the question of costs itself. This was criticised during the debate in the National Council in December 2020, and the then health minister announced a review of the effectiveness and efficiency of cannabis therapies.6 In its 2025 FAQ, the FOPH still states that no cannabis medicines are on the benefits catalogue.2
Figures that often circulate on the internet partly come from Germany. There, according to the Federal Government, the statutory health insurers rejected around 40 per cent of applications since 2017.7 The German system is regulated differently. This figure cannot be transferred to Switzerland.
What this means for your application
A rate says little about your case. What matters are the diagnosis, previous treatments and how well the application is justified. Your doctor submits the application. In practice, it is more likely to succeed once you have paid for the therapy yourself at first and its effect is documented.4
The evaluation also describes a middle way: with a therapeutic trial, the insurer agrees in advance to cover the costs if a benefit can be demonstrated in the individual case.3 Whether this is an option in your case is clarified by your doctor with the insurer. What treatment costs without cost approval is shown on the Costs page.
How it works at evidena
At evidena, the doctor decides after the consultation whether treatment with cannabis medicines is an option. If a prescription is issued, it must be filled at a pharmacy within one month. As a rule, it covers the need for one month, in justified cases up to three months. We cannot promise cost coverage by the health insurer.
You can book an appointment at portal.evidena.care. We answer questions via WhatsApp or at info@evidena.care. The process is described on the page How it works.
Conclusion
How often health insurers grant cost approval for cannabis has not been published for the period after 2018. The last public figures give 47 per cent for 2017 and 64 per cent for 2018, with clear differences between insurers. What counts for your application are the circumstances of your individual case, not a rate.
Frequently asked questions
What is the approval rate for cannabis with health insurers?
No current rate has been published. The most recent public figures, from an evaluation commissioned by the FOPH, give 47 per cent for 2017 and 64 per cent for 2018.
Are there figures for 2026?
No. According to our research, neither the FOPH nor the insurers have published approval rates for cannabis for the years after 2018.
Did the 2022 change in the law change cost coverage?
No. The change concerned narcotics law. It did not regulate who bears the costs. Reimbursement is still only possible in individual cases under Art. 71a to 71d KVV.
Does approval depend on the health insurer?
The evaluation commissioned by the FOPH found clear differences between insurers across all medicines. No figures per insurer have been published for cannabis alone.
Can evidena say how often a cost approval succeeds?
No. We have no figures of our own on this and therefore do not state a rate. Whether an application makes sense in your case is something you discuss with your doctor.
Sources
- Verordnung über die Krankenversicherung (KVV), SR 832.102, Art. 71a, 71b und 71d, Fassung vom 1. August 2026, Fedlex (accessed 13 November 2026)
- FAQ Cannabisarzneimittel, Bundesamt für Gesundheit BAG, 4. März 2025 (accessed 13 November 2026)
- BSS Volkswirtschaftliche Beratung, asim. Evaluation der Vergütung von Arzneimitteln im Einzelfall nach den Art. 71a–71d KVV, Schlussbericht im Auftrag des BAG, 24. Juli 2020 (accessed 13 November 2026)
- Cannabis für Schwerkranke, Bericht des Bundesrates in Erfüllung der Motion Kessler 14.4164, 4. Juli 2018 (accessed 13 November 2026)
- Bericht MeCanna 2022-2023, Auswertung der Meldungen 1. August 2022 bis 31. Juli 2023, Bundesamt für Gesundheit BAG, Februar 2025 (accessed 13 November 2026)
- Medizinalcannabis soll einfacher verschrieben werden können, Keystone-SDA, swissinfo.ch, 8. Dezember 2020 (accessed 13 November 2026)
- Antwort der Bundesregierung auf die Kleine Anfrage Drucksache 19/21484, Deutscher Bundestag, Drucksache 19/22651, 17. September 2020 (accessed 13 November 2026)